Loading…
Shanghai-based pharmaceutical manufacturer selling drugs in China.
Shanghai-based pharmaceutical manufacturer selling drugs in China.
Moat: none
Headquarters: Shanghai, China · Employees: 437
Size Shanghai Yizhong Pharmaceutical (688091.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.13B, the 2066th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥36.55 on 6 Nov 2026.
Performance Over six months the shares fell 34.0%, against -14.4% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 32.1% over the last twelve months (peer median -2.5%); the operating margin is 13.6% (peer median 7.6%).
Valuation It trades at 22.0× enterprise value to sales against a peer median of 4.3× (3rd most expensive of 19).
Capital Return on invested capital runs 1.1 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥326M | CN¥315M | CN¥173M | CN¥359M | CN¥235M |
| Revenue growth | — | +83% | -52% | +53% | — |
| Gross profit | CN¥285M | CN¥260M | CN¥158M | CN¥335M | CN¥217M |
| EBITDA | n/a | CN¥57.7M | -CN¥4.15M | CN¥168M | CN¥116M |
| Net income | CN¥69.7M | CN¥64.6M | CN¥6.98M | CN¥162M | CN¥143M |
| Free cash flow | -CN¥21.1M | -CN¥143M | -CN¥68.0M | CN¥73.6M | CN¥101M |
| Capital expenditure | CN¥58.5M | CN¥130M | CN¥80.0M | CN¥8.78M | CN¥35.9M |
| Total debt | CN¥25.0M | CN¥25.5M | CN¥0 | CN¥44.0M | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688091.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.1% | -6.9% | 8th highest of 21 |
| 6-month return | -34.0% | -14.4% | 6th lowest of 21 |
| Distance from 52-week high | -44.8% | -35.5% | 8th lowest of 21 |
| Revenue growth (TTM) | +32.1% | -2.5% | 2nd highest of 19 |
| Operating margin | 13.6% | 7.6% | 7th highest of 19 |
| EV / Sales | 22.0× | 4.3× | 3rd most expensive of 19 |
| ROIC minus cost of capital | -1.1 pp | +0.1 pp | 7th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | 22.0× | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 4.6× | 1.5% | +18.7% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 2.5× | 1.1% | +22.8% |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | 51.0× | n/a | n/a |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 3.8× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | 1.6× | 3.3% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 11.8× | 49.0% | +13.8% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | 7.6× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | 2.5× | 1.4% | -4.2% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 4.3× | 13.9% | +4.9% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 6.3× | 16.2% | +19.4% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 4.3× | 8.6% | -4.5% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 8.3× | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 1.6× | -3.0% | +4.2% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 1.4× | n/a | n/a |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 2.5× | 5.8% | +11.3% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 0.8× | 8.3% | +5.8% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 4.5× | 5.5% | +7.7% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | 94.5× | 10.4% | -60.6% |